About This Alzheimer's Study
As quoted by Jessica Smith from the Alzheimer's Society's website about Tau research.
“We know that tangles of Tau, a protein found in the brain, are a hallmark of Alzheimer's disease, a cause of brain cell death. Investigating drug treatments that have the potential to stop these tau tangles occurring is an interesting research avenue to explore.
After hearing recently that drug companies are scaling back their research into treatments for Alzheimer's disease, it's really encouraging to see a study that has reached the clinical trial stage and that investment is still being made.”— Jessica Smith
Alzheimer's Society, UK
This global Phase 3 Alzheimer's clinical trial is being conducted in 20 countries located in North America, Asia, Australia, and Europe. The purpose of the study is to examine the safety and effectiveness of the study drug called LMTX™. LMTX™ aims to dissolve the tangles in the brain associated with Alzheimer's disease.
One study will involve 833 people with mild to moderate Alzheimer's disease over 14 months. Another study will include 500 people with mild Alzheimer's disease over 22 months. Both studies will be conducted in North America, Asia, Australia, and Europe. (Click here for a map of study locations.)
Study participants must be:
- Diagnosed with mild or moderate Alzheimer's disease
- Undiagnosed and experiencing noticeable memory loss issues
- Under the age of 90
Additionally, study participants must have a caregiver who:
- Sees the participant 2 hours or more per day on 3 days or more per week (on average)
- Is willing to provide written informed consent for both themselves and the study participant
- Is able to read, understand, and speak the designated language at the study site
- Will accompany the person with Alzheimer's to each clinic visit
- Is able to ensure that the study drug is given to the participant as required
Those who participate in this study will receive at no cost:
- Study-related care from a team of medical professionals
- All study-related exams and tests
- Access to study drug, LMTX™ after the study ends
Reimbursement for time, travel and accommodations may be provided
What is my role as a caregiver?
As a caregiver, you will play an active role throughout the study. You will be asked to accompany the person with Alzheimer’s at each clinic visit and also to provide structured feedback about the participant’s health, memory, and daily living activities. Medical imaging will be used to carefully measure the effect of treatment. Other routine medical tests, including urinalysis will be performed.
While taking part in a clinical trial involves commitment and time, many people find participation to be worthwhile. Time spent with the clinical research team is empowering, and educational. Above all, it is important to know that you and your loved one may help bring a new treatment forward that may halt or slow Alzheimer’s disease progression.